|
|
|
 |
| |
|
|
| |
We are pleased to announce that the following people will be speaking on the Healthcare Panel:
|
| |
Dr Ulrich Geilinger, Investment Adviser, HBM Partners |
| |
Dr Simon Turton, Director, Warburg Pincus |
| |
Andrew Fraser, Director, 3i |
| |
Dr William Brooks, Director, Quest Management |
| |
|
| |
This panel will be moderated by: |
| |
Dr Michael Liang, Associate, Advent Venture Partners |
| |
|
| |
The panel discussion will focus on the following issues: |
| |
Early stage biotechnology:
- Where is the funding for early stage companies?
- Are venture capitalists truly looking for later stage opportunities?
- What happens to the “pipeline” of deals if a certain sector is ignored?
Exits: IPO and M&A:
- Will there be more biotechnology flotations over the coming year?
- Is M & A favourable to IPO, and what are the deciding factors?
Exciting Technology:
- Are there specific areas of biotechnology to target or avoid?
- Speciality pharma models – will there be more of these? Will this model ultimately succeed? |
|
|
|
|
|
